Could a simple protein infusion limit stroke damage?

NCT ID NCT07415655

Recruiting now Disease control Sponsor: University Hospital Hradec Kralove Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether a low dose of albumin, a natural blood protein, can protect brain tissue after an ischemic stroke. One hundred participants will receive either albumin or a placebo during a standard procedure to restore blood flow. The goal is to see if albumin reduces brain injury and improves neurological outcomes over 90 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Albumin (human serum albumin)
What this could lead to: If it works, this could point toward a simple, safe treatment to limit brain damage after a stroke and improve patients' recovery.
What could go wrong: This is an early Phase 2 trial with only 100 people, so results may not be conclusive. The benefit over standard care is unproven, and albumin may not protect the brain as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ISCHEMIC STROKE

Contacts and locations

Locations

University Hospital Hradec Kralove
RECRUITING

Hradec Králové, Czech Republic, 50005, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.